STOCK TITAN

Telemark discloses 4.1% Biodesix (BDSX) stake in final Schedule 13G/A

Filing Impact
(Moderate)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13G/A

Rhea-AI Filing Summary

Telemark Asset Management, Telemark Fund and Colin McNay have filed an Amendment No. 1 to their Schedule 13G for Biodesix, Inc., which they state is a final, “exit” filing. The reporting persons may be deemed to beneficially own 327,824 shares of Biodesix common stock, representing approximately 4.1% of the outstanding shares as of the event date.

All 327,824 shares are reported with shared voting and shared dispositive power and no sole voting or dispositive power. The filers certify that the securities were not acquired and are not held for the purpose of changing or influencing control of Biodesix, but instead under the passive ownership standard applicable to Schedule 13G.

Positive

  • None.

Negative

  • None.





Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)






SCHEDULE 13G




Comment for Type of Reporting Person: Note to rows 6, 8, 9 and 11: This Amendment No. 1 to Schedule 13G (this "Amendment") amends, in its entirety, the statement on Schedule 13G originally filed with the U.S. Securities and Exchange Commission on June 24, 2024 (the "Prior Schedule 13G") by the Reporting Persons (as defined herein). This Amendment is the final amendment to the Prior Schedule 13G and constitutes an exit filing for the Reporting Persons.


SCHEDULE 13G




Comment for Type of Reporting Person: Note to rows 6, 8, 9 and 11: This Amendment amends, in its entirety, the Prior Schedule 13G by the Reporting Persons. This Amendment is the final amendment to the Prior Schedule 13G and constitutes an exit filing for the Reporting Persons.


SCHEDULE 13G




Comment for Type of Reporting Person: Note to rows 6, 8, 9 and 11: This Amendment amends, in its entirety, the Prior Schedule 13G by the Reporting Persons. This Amendment is the final amendment to the Prior Schedule 13G and constitutes an exit filing for the Reporting Persons.


SCHEDULE 13G



Telemark Asset Management, LLC
Signature:/s/ Brian C. Miley
Name/Title:Brian C. Miley, Chief Financial Officer
Date:01/23/2026
Telemark Fund, LP
Signature:By: Telemark Asset Management, LLC, investment adviser, /s/ Brian C. Miley
Name/Title:Brian C. Miley, Chief Financial Officer
Date:01/23/2026
Colin S. McNay
Signature:/s/ Colin S. McNay
Name/Title:Colin S. McNay, President and sole owner of Telemark Asset Management, LLC
Date:01/23/2026

FAQ

What does the Telemark Schedule 13G/A say about its Biodesix (BDSX) ownership?

The filing states that Telemark Asset Management, Telemark Fund and Colin McNay may be deemed to beneficially own 327,824 shares of Biodesix common stock, representing approximately 4.1% of the outstanding shares.

Why is this Biodesix (BDSX) Schedule 13G/A labeled an exit filing?

The amendment notes that it amends in its entirety the prior Schedule 13G and that it is the final amendment, explicitly stating that it constitutes an exit filing for the reporting persons.

How much voting and dispositive power does Telemark report over Biodesix (BDSX) shares?

Each reporting person shows 0 shares with sole voting or dispositive power and 327,824 shares with shared voting and shared dispositive power.

Does Telemark state an intent to influence control of Biodesix (BDSX)?

No. The certification states the securities were not acquired and are not held for the purpose of changing or influencing control of Biodesix and are not held in connection with any such transaction, consistent with a passive Schedule 13G filing.

Who are the reporting persons in this Biodesix (BDSX) Schedule 13G/A?

The amendment is jointly filed by Telemark Asset Management, LLC, Telemark Fund, LP, and Colin S. McNay. Telemark Asset Management is the investment adviser to Telemark Fund, and McNay is Telemark Asset Management’s president and sole owner.

What percentage threshold does the Biodesix (BDSX) 13G/A reference?

Item 5 indicates ownership of 5 percent or less of the class, with the reported beneficial ownership at approximately 4.1% of Biodesix’s outstanding common stock.
BIODESIX INC

NASDAQ:BDSX

BDSX Rankings

BDSX Latest News

BDSX Latest SEC Filings

BDSX Stock Data

88.31M
3.68M
54.51%
24.32%
2.1%
Diagnostics & Research
Services-medical Laboratories
Link
United States
LOUISVILLE